Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.

Abstract

Epidemiological studies report a beneficial relationship between drinking coffee and the risk of developing Parkinson's disease (PD). This is likely due to caffeine, a constituent of coffee, acting as an adenosine A2A receptor antagonist. This study was planned to investigate whether caffeine has any effect on the aggregation of α-synuclein, present in Lewy bodies, the pathological hallmark of PD, which may account for this positive association. Aggregation of recombinant α-synuclein was followed in vitro and in a well-validated yeast proteotoxicity model of PD. Caffeine was found to have twin effects: it accelerated the process of aggregation and also altered the nature of mature aggregates. Aggregates formed in the presence of caffeine displayed amorphous as well as fibrillar morphology. In the presence of caffeine, the toxicity of oligomers and aggregates was diminished, with concomitant reduction in intracellular oxidative stress, decreased oxidative proteome damage, and increased cell survival. Caffeine-treated samples showed improved binding to phospholipids, a property likely to be important in cellular functioning of α-synuclein. Far-UV CD spectroscopy and fluorescence quenching analysis revealed that caffeine induced transient changes in this intrinsically disordered protein, forming a non-native species that enhanced the rate of aggregation of α-synuclein and modified the population of mature aggregates, introducing a higher fraction of amorphous, less toxic species. Increasingly, it is felt that the process of fibrillation itself, along with the nature of mature aggregates, dictates the cytotoxicity of the process. Our results provide a rationale for the observed epidemiological link between drinking coffee and developing PD.

• Authors: Jay Kardani, Ipsita Roy
• Journal: ACS chemical neuroscience (ACS Chem Neurosci) Vol. 6 Issue 9 Pg. 1613-25 (Sep 16 2015) ISSN: 1948-7193 [Electronic] United States
• PMID: 26167732 (Publication Type: Journal Article)

Chemical References

• Antiparkinson Agents
• Protein Aggregates
• Reactive Oxygen Species
• Recombinant Proteins
• SNCA protein, human
• alpha-Synuclein
• Caffeine

Topics

• Animals
• Antiparkinson Agents (pharmacology)
• Caffeine (pharmacology)
• Cell Survival (drug effects)
• Drug Evaluation, Preclinical
• Erythrocytes
• Humans
• Oxidation-Reduction
• Oxidative Stress (drug effects, physiology)
• Parkinsonian Disorders (drug therapy, metabolism)
• Protein Aggregates (drug effects)
• Rats
• Reactive Oxygen Species (metabolism)
• Recombinant Proteins (genetics, metabolism)
• Saccharomyces cerevisiae
• alpha-Synuclein (genetics, metabolism)